Search results
Results From The WOW.Com Content Network
Estrogen dosages for prostate cancer; Route/form Estrogen Dosage Ref(s) Oral: Estradiol: 1–2 mg 3x/day [1] Conjugated estrogens: 1.25–2.5 mg 3x/day [2] [3] Ethinylestradiol: 0.15–3 mg/day [2] [3] [4] Ethinylestradiol sulfonate: 1–2 mg 1x/week [5] [3] [6] Diethylstilbestrol: 1–3 mg/day [2] [7] Dienestrol: 5 mg/day [8] Hexestrol: 5 mg ...
Estrogen dosages for prostate cancer Route/form Estrogen Dosage Oral: Estradiol: 1–2 mg 3x/day Conjugated estrogens: 1.25–2.5 mg 3x/day Ethinylestradiol: 0.15–3 mg/day Ethinylestradiol sulfonate: 1–2 mg 1x/week Diethylstilbestrol: 1–3 mg/day Dienestrol: 5 mg/day Hexestrol: 5 mg/day Fosfestrol: 100–480 mg 1–3x/day Chlorotrianisene ...
A study that used high- to very-high-dose oral estradiol to treat postmenopausal women with estrogen receptor-positive breast cancer found that mean steady-state estradiol levels in the 6 mg/day group were about 300 pg/mL and in the 30 mg/day group were about 2,400 pg/mL. [37]
Estrogen dosages for menopausal hormone therapy; Route/form Estrogen Low Standard High Oral: Estradiol: 0.5–1 mg/day: ... Estrogen dosages for breast and prostate ...
The median effective dose is the dose that produces a quantal effect (all or nothing) in 50% of the population that takes it (median referring to the 50% population base). [6] It is also sometimes abbreviated as the ED 50, meaning "effective dose for 50% of the population". The ED50 is commonly used as a measure of the reasonable expectancy of ...
Polyestradiol phosphate (PEP), sold under the brand name Estradurin, is an estrogen medication which is used primarily in the treatment of prostate cancer in men. [1] [9] [2] [10] It is also used in women to treat breast cancer, as a component of hormone therapy to treat low estrogen levels and menopausal symptoms, and as a component of feminizing hormone therapy for transgender women.
The International Classification of Diseases for Oncology (ICD-O) is a domain-specific extension of the International Statistical Classification of Diseases and Related Health Problems for tumor diseases. This classification is widely used by cancer registries. It is currently in its third revision (ICD-O-3). ICD-10 includes a list of ...
Estradiol only recommended for use for the shortest period of time and at the lowest effective dose due to its adverse-effects profile. [29] There is the potential for a range of adverse effects in breasts, skin, eyes, cardiovascular, gastrointestinal, genitourinary or central nervous systems. [29]